Want to see IDXG full AI Analyst Report?
IDXG Stock Chart & Stats
$1.46
$0.08(5.79%)
At close: 4:00 PM EDT
$1.46
$0.08(5.79%)
Day’s Range― - ―
52-Week Range$0.77 - $2.40
Previous CloseN/A
Volume320.00
Average Volume (3M)11.58K
Market Cap
$46.26M
Enterprise Value$43.46
Total Cash (Recent Filing)$2.69M
Total Debt (Recent Filing)$974.00K
Price to Earnings (P/E)0.3
Beta1.53
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.38
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating and free cash flow across 2023–2025 and into TTM 2026 supports internal funding of operations, reduces reliance on external financing, and underpins sustainable investment in the lab and clinical operations. This durability improves resilience through cyclical demand swings.
Improved Profitability & MarginsSharply improved net income and stable high gross margins (~59–64%) indicate the company’s test economics are favorable and that recent operating changes have raised earnings quality. Sustained margins make the business more cash generative and better able to invest in clinical validation and sales.
Lower Leverage And Improved FlexibilityMaterial debt reduction and modest leverage in 2025/TTM 2026 enhance financial flexibility, lowering refinancing and interest risk. A lean capital structure gives management optionality to pursue partnerships, targeted R&D, or working-capital needs without immediate pressure from creditors.
Bears Say
Revenue VolatilityDeclines in revenue across 2025 and in the trailing twelve months point to unstable demand or reimbursement mix; inconsistent top-line trends weaken predictability of cash flow and make long-term planning, contract negotiations with payors, and scaling of lab capacity more difficult.
Prior Negative EquityA recent return from multi-year negative equity highlights past solvency stress and raises the bar for sustained performance. This history can constrain credit options, increase scrutiny from partners and payors, and leaves less margin for error if operating conditions deteriorate again.
Limited Scale / VolumeRelatively small employee base and modest specimen volume limit scale economies and bargaining power with payors and suppliers. Combined with steep recent revenue contraction, limited scale may restrict growth opportunities and make fixed-cost absorption and margin expansion harder over the medium term.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.77 and its highest was $2.40 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $46.26M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Nov 11, 2026 which is in 88 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Aug 10, 2026. The company reported $0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.
Technical Analysis
Ownership Overview
83.99% Insiders
<0.01% Other Institutional Investors
16.00% Public Companies and
Individual Investors